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Abstract 
    Background: Thiamine deficiency contributes to hyperglycemia and diabetes complications. Thus, in this study, the effect of thiamine 
pyrophosphate (TPP) on the in vivo and in vitro formation of glycation, oxidative stress, and inflammatory markers (the main contributors 
of vascular diabetes complications) was examined in type 2 diabetes rat model.  
   Methods: Type 2 diabetes was induced in rats with a combination of streptozotocin and nicotinamide (55+200 mg/kg). Two groups 
of rats, healthy and diabetic, were treated with 0.1% TPP in drinking water daily for 3 months and the 2 others received water only. The 
glucose, insulin, early to end glycation products, the activity of glyoxalase system, lipid profile, LDL oxidation markers, inflammatory 
markers, creatinine in the serum, and proteinuria in the urine of all rats were determined. Moreover, albumin and LDL were incubated 
with glucose in the presence and absence of TPP, and the samples were investigated for glycation and oxidation products. Different 
variables in all 4 groups were compared with multiple analysis of variance (MANOVA-Tukey) test using SPSS version 16.  Significance 
level was set at p<0.05. 
   Results: TPP decreased the formation of diverse glycation and oxidation products in both in vivo (glycated LDL= 144.50±3.48 and 
oxidized LDL= 54.08±2.67 μmol/l) and in vitro (glycated LDL= 107.00±2.82 and oxidized LDL= 50.83±1.22 μmol/l). In addition, the 
vitamin reduced fasting blood sugar (9.23±0.29), insulin resistance (9.10±0.50), tumor necrosis factor-α (285.43±15.97), interleukin-6 
(257.65±13.06), and improved the lipid profile, the activity of Glo system (Glo-I= 31.65±1.06 and Glo-II= 27.01±0.90 U/mL) and renal 
function in the diabetic rat (p<0.001).  
   Conclusion: TPP decreased the major risk factors for diabetic complications and corrected the alternations of glucose and lipid 
metabolism in type 2 diabetic rats; thus, it is recommended for diabetes treatment. 
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Introduction 
Type 2 diabetes mellitus is one of the most common dis-
eases in the world that causes serious health and economic 
challenges. Hyperglycemia causes vascular diabetes com-
plications owing to the induction of glycation, oxidative 
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↑What is “already known” in this topic: 
Hyperglycemia causes vascular diabetes complications owing to the 
induction of glycation, oxidative stress, and inflammation. 
Moreover, atherosclerosis and nephropathy are the main cause of 
death in these patients. thiamine deficiency leads to hyperglycemia 
and diabetes complications. 
 
→What this article adds: 
We suggested that thiamine pyrophosphate as an active form of the 
vitamin reduces glycation, oxidative stress, and inflammation 
markers as cardinal risk factors of vascular complications. Further, 
we proposed the vitamin improved activity of glyoxalase system, 
renal function and insulin sensitivity. 
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stress, and inflammation (1). Moreover, atherosclerosis and 
nephropathy are the main causes of death in these patients 
(2).  
Glycation products are the cardinal mediators of insulin 
resistance, β cell failure, and diabetes disorders (3). Gly-
cated LDL (g-LDL) and its oxidized form (Ox-LDL) con-
tribute to the initiation and progression of atherosclerosis 
(4). The production of toxic carbonyl active species, such 
as glioxal (GO) and methylglyoxal (MGO), which is one of 
the consequences of oxidation of lipids and sugars, leads to 
carbonyl stress. Furthermore, this phenomenon is responsi-
ble for the activation of a series of inflammatory responses 
leading to accelerated vascular damage in diabetes (5). Gly-
oxalase system is the most potent enzymatic system for the 
prevention and reduction of carbonyl stress (6).  
Thiamine is an antioxidant and a vital cofactor in the car-
bohydrate metabolism. Also, thiamine deficiency leads to 
hyperglycemia and diabetes complications (7). In this 
study, the effect of thiamine pyrophosphate (TPP) on gly-
cemic, oxidative and inflammatory stress, as major risk fac-
tors for vascular disorders in diabetic rats, was studied. 
Also, the effect of treatment on the production of low gly-
cemic and oxidized albumin and lipoprotein products in 
vitro was also investigated.  
 
Methods  
Materials 
All materials were in analytical grade and purchased 
from Sigma or Merck Chemical Companies. 
 
In vivo studies 
Animal model of type 2 diabetes 
Eight weeks old male Wistar rats, weighing 180±15, 
were purchased from the Pasteur Institute, Karaj, Iran. An-
imals were housed under controlled temperature conditions 
with a 12-hour light and 12-hour dark cycle, with free ac-
cess to food and water. After 2 weeks, they were divided 
into 2 main groups. After a 12-hour fasting, type 2 diabetes 
was induced in group 1 by single intraperitoneally (i.p.) in-
jection nicotinamide (210 mg/kg body weight in the Na-
citrate buffer, pH 4.5) and streptozotocin (55 mg/kg body 
weight in the citrate buffer, 15 min later) (8). 
After 3 days, animals with fasting blood sugar of (FBS) 
> 11 mmol/L were considered diabetic. Then, each of the 2 
main (diabetic and normal) groups was divided into 2 sub-
groups, with 10 rats in each: subgroup 1: D (for the diabetic 
group) and N (for the control group), with no more treat-
ments; subgroups 2: D (TPP) and N (TPP) received 0.1%  
thiamine pyrophosphate (TPP) in drinking water daily for 
3 months. The dose of thiamine was selected according to 
the literature (9) and the authors’ experience.  
All groups fed on a standard chow diet. The experimental 
protocol was approved by the Animal Ethical Committee in 
accordance with the guidelines for the care and use of la-
boratory animals prepared by Ardabil University of Medi-
cal Sciences. 
At the end of the experiment, after a 16-hour fast, rats 
were anesthetized with an i.p injection of ketamine - xylo-
sine (90+10 mg/kg body mass). Then, a blood sample was 
collected from their heart and transferred into the test tubes 
with and without EDTA. Serum samples were prepared by 
15-minute centrifugation of blood at 5000×g and were 
stored at −70°C for measurements. Their kidneys were dis-
sected and weighted promptly. The kidney weight index 
was calculated by dividing kidney weight to rats’ body 
weight.  
 
Determining biochemical parameters  
Fasting blood sugar (FBS), triglyceride (TG), total cho-
lesterol (TC), LDL, HDL, serum creatinine (Cr), and pro-
tein excretion in urine (PU) were measured by photometric 
methods. Moreover, the atherogenic index was computed 
with LDL/HDL ratio. The serum insulin level was deter-
mined by the enzyme-linked immunosorbent assay 
(ELISA) method using a rat insulin kit (Mercodia, Uppsala, 
Sweden) and HOMA-IR (homeostasis model assessment of 
insulin resistance) was calculated as explained previously 
(4).  
 
Determining glycated products 
Glycated albumin (g-Alb) was quantified by a colorimet-
ric method using nitroblue tetrazolium chloride (10). Gly-
cated LDL was determined by the reaction of extracting 
LDL with oxalic acid and thiobarbituric acid to yield the 
hydroxymethylfurfuraldehyde chromogen (11, 12). Gly-
oxal (GO) and methylglyoxal (MGO) were assayed by a 
reverse phase HPLC (10). The fluorescent AGEs were de-
termined in the serum of rats (4). 
 
Determining oxidative stress markers  
Conjugated dienes (CD) in LDL lipids, as early products 
of LDL oxidation, was analyzed spectrometrically at 234 
nm. The molar extinction coefficient of CD is 2.95 × 104 
M-1 and the results were presented as µM. Fluorescence in-
tensity of end oxidation product of LDL, named oxidation 
fluorescent product (OFP), was recorded at the emission 
maximum 430 nm upon excitation at 360 nm (10).   
Advanced oxidation protein products (AOPP) was deter-
mined based on the spectrophotometric detection, accord-
ing to the method of Witko-Sarsat et al, as described in our 
recent papers (4, 13). Levels of malondialdehyde (MDA) 
and glutathione (GSH) were determined with a commercial 
assay kit (Cayman Chemical Co., Ann Arbor, MI). 
 
Determining inflammatory markers 
 Tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-
6) were determined using ELISA kits (Immunotech, 
France).  
 
Enzymatic assay 
The activity of GLO-1in hemolysate was determined by 
measuring the initial rate of S-D-lactoylglutathione for-
mation, while the rate of its hydrolysis was a measure of the 
activity of GLO-2 in all samples and expressed as unit/mL 
(10, 14). 
 
In vitro albumin and LDL glycation and oxidation 
Albumin extraction and glycation 
Rat serum albumin (RSA) was extracted and incubated 
with glucose in the absence and presence of TPP (100 
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mg/L). The extraction and incubation procedures were sim-
ilar to what was explained previously (4). 
 
Determining various glycated products of albumin 
All measurements were done at least 3 times, and in case 
of incompatibility, the experiment was repeated. The g-
Alb, MGO, GO, and fluorescent AGEs in the tubes contain-
ing the reaction mixtures were measured using the methods 
explained in the in vivo section.  
 
Purification and formation of glyco-oxidation products 
of LDL 
LDL was isolated with heparin and incubated in the pres-
ence and absence of glucose and TPP (100 mg/L). The 
complete procedure of the study was similar to that we ex-
plained before in this article (4).  
 
Determining glycated and oxidized LDL products 
The glycated and oxidized LDL products were measured 
using the methods explained in the in vivo section. 
 
Statistical analysis 
All data were expressed as mean±S.D (standard devia-
tions).  Different variables in all 4 groups were compared 
with one-way multiple analysis of variance (MANOVA-
Tukey) test using SPSS version 16. Significance level was 
set at p<0.05. 
 
Results 
The results of the in vivo experiment 
The levels of fasting blood sugar, insulin, HOMA-IR, li-
pid profile, and kidney function tests in the rat groups are 
represented in Table 1. FBS, HOMA index, as a marker of 
insulin resistance, TG, TC, LDL, and the atherogenic index 
increased significantly in the diabetic rats compared to the 
healthy group (Table 1). Thiamine pyrophosphate signifi-
cantly reduced the parameters in diabetic rats. The treat-
ment decreased the levels of TG, TC, and the atherogenic 
Table 1. The effect of thiamine pyrophosphate (TPP) on fasting blood sugar, insulin, HOMA-IR, and glycation products of the healthy and diabetic rats 
Variable Groups p 
N N (PLP+THC) D D (PLP+THC) < 0.001 
Blood sugar (mmol/L) 4.50 ± 0.27 4.45± 0.27 15.73 ± 0.46N 9.23 ± 0.29N, D < 0.001 
Insulin (µU/mL) 17.04 ± 0.90 16.97± 0.87 13.03 ± 0.71N 11.72 ± 0.34N, D < 0.001 
HOMA-IR  3.40 ± 0.427 3.35 ± 0.24 9.10 ± 0.50N 4.80± 0.20N, D < 0.001 
Triglyceride (mmol/L) 0.92 ± 0.02 0.88 ± 0.02N, D 3.10 ± 0.16 N 1.81 ± 0.08 N, D < 0.001 
Total cholesterol (mmol/L) 2.66 ± 0.07 2.35 ± 0.08 N, D 4.33 ± 0.24 N 3.45 ± 0.18 N, D < 0.001 
HDL (mmol/L) 1.31 ± 0.06 1.27 ± 0.05 0.48 ± 0.01 N 1.00 ± 0.03 N, D < 0.001 
LDL (mmol/L) 0.58± 0.01 0.53 ± 0.02 2.61 ± 0.24 N 1.53 ± 0.16 N, D < 0.001 
HDL/LDL 0.44 ± 0.01 0.41 ± 0.01 N, D 5.43 ± 0.49 N 1.53 ± 0.11 N, D < 0.001 
Creatinine (µmol/L) 59.65±3.87 65.70±4.29 105.73 ± 6.53N 83.08 ± 5.09N, D < 0.001 
Proteinuria (mg/24 h) 11.73 ± 0.95 9.35 ± 0.81 320.62 ± 17.63N 65.25 ± 3.92N, D < 0.001 
Kidney weight index  0.77 ± 0.05 0.75 ± 0.04 1.350.77±0.71N 0.81±0.05D < 0.001 
N indicates significance of data comparing group N (normal) with other groups  
D indicates significance of data comparing group D (diabetic) with other groups  
 
 
Fig. 1. Effect of thiamine pyrophosphate on the activity of glyoxalase system in healthy and diabetic rats: (A) Activity of glyoxalase-I; (B) Activity of glyoxalase-ΙΙ. 
a indicates significance of data comparing  the healthy group (N) with other groups (p<0.001). 
b indicates significance of data comparing group diabetic (D) with other groups (p<0.001). 
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index in the treated healthy rats compared to untreated rats 
(p<0.001). 
Glyoxalase-I and II activities in treated and untreated rat 
groups are presented in Figure 1. Diabetes induction in rats 
decreased the activity of Glo system, but the vitamin in-
duced the activity of Glo-I and Glo-II in the healthy and 
diabetic rats (p<0.001). 
Comparison of the effect of the treatment on glycation (g-
Alb, g-LDL, GO, MGO, and AGES), oxidative stress (early 
and end oxidation products of LDL, AOPP, MDA, and 
GSH), and inflammatory (TNF-α and IL-6) markers in the 
named groups is represented in Table 2. Levels of gly-
cation, oxidative stress, and inflammatory markers de-
creased in the treated diabetic rats than in the untreated, but 
GSH level was higher in the treated than in the untreated 
diabetic rats (p<0001). Furthermore, the levels of the gly-
cation and inflammatory markers were lower in the healthy 
rats compared to the untreated rats (p<0.001). 
 
The results of the in vitro study 
The effects of TPP on the in vitro formation of various 
glycation products (early to end) of RSA and LDL gly-
cation and oxidation (early and end) products are presented 
in Table 3. The vitamin diminished the levels of early (g-
Alb), intermediate (GO and MG), and end products (AGEs) 
of glycation as well as LDL glycation and oxidation prod-
ucts.  
 
 
Discussion 
The effect of thiamine pyrophosphate on the activity of 
the glyoxalase system, various glycation products (early to 
end), oxidative stress markers, as early and end oxidation 
products of LDL, as well as advanced oxidation protein 
products (AOPP) has not been explored in rats with type 2 
diabetes. In this study, thiamine pyrophosphate reduced 
various glycation, oxidative stress, and inflammatory mark-
ers, as risk factors of vascular diabetes complications, in 
rats with type 2 diabetes. Moreover, the treatment showed 
a beneficial effect on glucose metabolism, lipid profile, gly-
oxalase system activity, and kidney function. Also, in vitro 
inhibitory property of the vitamin on the diverse glycation 
and oxidation products of albumin and LDL was observed.  
Diabetes and thiamine deficiency reduce the activity of 
the glutoxylase system. TPP decreased blood glucose along 
with improving insulin action in the diabetic rats. Insulin 
and HOMA-IR levels were, respectively, higher and lower 
(p<0.001) in treated diabetic rats than in the untreated 
group (Table 1). Thiamine is necessary for insulin synthesis 
and secretion (15). In the thiamine-deficient state, glucose 
undergoes metabolism via alternate pathways, which can 
result in insulin resistance and complications (16).  The gly-
oxalase system decreases dicarbonyl compounds and AGEs 
(17). Diabetes and deficiency of thiamine reduce the activ-
ity of Glo system. Moreover, thiamine deficiency is com-
mon in diabetes (4, 10). Various glycation products, includ-
ing glycated albumin, dicarbonyl compounds, and AGEs, 
have been known as the sources of oxidative stress and in-
flammatory markers that induce insulin-resistance, hyper-
tension, neurodegenerative disease, and diabetic vascular 
complications (18, 19). AGEs may interfere in the insu-
linsecretion (20). Prerhaps, AGEs were involved in the 
pathogenesis of insulin resistance and accelerated athero-
sclerosis in diabetes through the induction of oxidative 
stress and inflammation (21). In this study, TPP, as a potent 
Table 2. Effect of thiamine pyrophosphate (TPP) on the lipid profile of healthy and diabetic rats 
Variable Groups p 
N N (TPP) D D (TPP) < 0.001 
Glycated albumin (μmol/L) 110.65 ± 6.60 85.71 ± 5.40N, D 394.63 ± 16.65N 291.00 ± 14.40N, D < 0.001 
Glycated LDL (μmol/L) 51.13 ± 1.70 38.06 ± 0.85N, D 185.90 ± 6.77N 144.50 ± 3.48N, D < 0.001 
Glyoxal (μmol/L) 19.66 ± 0.91 9.82 ± 0.88N, D 121.70 ± 6.40N 52.38 ± 2.65N, D < 0.001 
Methylglyoxal (μmol/L) 20.01 ± 0.97 10.37 ± 0.90N, D 139.21 ± 5.10N 47.51 ± 2.37N, D < 0.001 
AGEs (FI, A.U) 52.07 ± 3.65 37.94 ± 2.48N, D 292.30 ± 13.67N 160.45 ± 7.06N, D < 0.001 
CD (μmol/L) 16.13±0.90 15.02±0.63 107.96 ± 4.83N 54.08 ± 2.67N, D < 0.001 
FOP (μmol/L) 233.73 ± 14.40 220.33 ± 11.71 510.93 ± 22.73N 330.55 ± 18.92N, D < 0.001 
AOPP (μmol/L) 24.57 ± 0.99 18.85 ± 0.86 79.84±5.01N 37.27±2.89N, D < 0.001 
MDA (μmol/L) 10.58± 1.31 8.53 ± 0.92 157.61 ± 7.24N 77.53 ± 4.16N, D < 0.001 
GSH (μmol/L) 175.58± 8.31 188.67 ± 9.01 88.43 ± 3.97N 145.61± 8.31N, D < 0.001 
TNF-α (μmol/L) 120.54± 7.31 90.67 ± 5.01N, D 285.43 ± 15.97N 200.61± 8.31N, D < 0.001 
Il-6 (μmol/L)  86.58±4.28 57.67 ± 2.31N, D 257.65 ± 13.06N 163.89± 6.35N, D < 0.001 
N indicates significance of data comparing group N with other groups (p<0.001) 
D indicates significance of data comparing group D with other groups (p<0.001) 
 
Table 3. The effect of thiamine pyrophosphate (TPP) on the in vitro formation of various glycated products of rat serum albumin (RSA) 
In
 v
itr
o 
Al
bu
mi
n 
Tube Content Rat serum albumin glycation products 
Glycated albumin 
(µmol/L) 
Methylglyoxal 
(µmol/L) 
Glyoxal 
(µmol/L) 
AGEs 
(AU) 
RSA 111.70±3.40 9.78±0.10 6.05±0.08 111.70±3.40 
RSA+ Glc 987.47±9.31 33.05±0.51 18.85±0.21 987.47±9.31 
RSA+ Glc + TPP 425.42±4.82 17.88±0.25 10.30±0.17 425.42±4.82 
  
Tube Content LDL glycation and oxidation products 
LD
L 
 Glycated LDL 
(µmol/L) 
Early oxidation products 
(µmol/L) 
End Oxidation products 
(AU) 
LDL 20.10±0.80 17.01±0.62 15.17±0.44 
LDL+ Glc 317.45±7.07 129.76±2.55 476.01±10.84 
LDL+ Glc + TPP 107.00±2.82 50.83±1.22 110.01±2.36 
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5 
antiglycating compound, induced the activities of glyoxa-
lase-1 and glyoxalase-2 (Fig. 1. A and 1.B) and decreased 
the early (g-Alb and g-LDL), intermediate (GO and MGO), 
and end glycation products (AGEs) in the treated healthy 
and diabetic rats (Table 2) (p<0.001). Further, the vitamin 
has in vitro antiglycating activity on diverse glycation prod-
ucts (Table 3). Based on the literature review, the effect of 
TPP on the Glo system activity in diabetes has not yet been 
investigated. The reducing effect of thiamine on the for-
mation of AGEs in vitro  and in vivo as well as MGO for-
mation in the in vitro were presented (22, 23). However, the 
effects of thiamine on different glycation products in vivo 
and in vitro was investigated. Thiamine may reduce differ-
ent glycation products with antioxidant property, dicar-
bonyl scavenger, and activation of the Glo system (24).  
Oxidative stress and inflammation stimulate insulin re-
sistance and diabetes complications (25). Thus, the treat-
ment decreased insulin resistance and intercepted athero-
sclerosis over and above amended nephropathy in the dia-
betic rats because of reducing oxidative stress. Over and 
above the treatment decreased advanced oxidation protein 
products and malondialdehyde, along with the elevation of 
glutathione level. Further, it abstracted TNF-α and IL-6 as 
inflammatory markers (Table 2). Previously, the anti-in-
flammatory effect of thiamine with reduction of cited in-
flammatory markers was reported in a chronic model of in-
flammation in the rat (26).  
 The rising levels of TG, LDL, and VLDL, along with a 
reduction of HDL, were observed in diabetic nephropathy, 
diabetic microalbuminuria, and thiamine deficiency (27, 
28). The treatment had a positive effect on the lipid profile 
in the healthy and diabetic rats (Table 1). The treatment de-
creased TG, TC, and the atherogenic index in the healthy 
and diabetic rats but reduced LDL only in the diabetic rats 
(p<0.001). Thiamine reduces lipogenesis in the liver and 
adipose tissue in glycemic condition (29).  
Glycated LDL is more sensitive to oxidation than the 
nonglycated of LDL. Oxidized LDL has a principal role in 
the initiation and progression of atherosclerosis (30). Gly-
cation and oxidation of LDL increase following glycemia, 
dyslipidemia, oxidative stress, and glycation (31, 32). The 
results of this study revealed an inhibitory effect of TPP on 
the glycation and oxidation of LDL in both conditions, in 
vivo (p<0.001) and in vitro (Tables 2 and 3) for the first 
time. The treatments that inhibit the formation of the end 
oxidation products of LDL can prevent the formation of any 
atheromatous lesions (4, 10).  
Diabetic nephropathy (DN) contributes to renal failure. 
Diabetes induction elevated urinary protein excretion, se-
rum creatinine, and kidney weight index in the rats (Table 
1). Moreover, a negative correlation was found between 
kidney weight index and renal function (4). The vitamin re-
duced the levels of kidney function markers in the diabetic 
rats (p<0.001). Furthermore, no difference was observed 
between kidney weight index in the treated diabetic rats and 
the healthy rats. Level of g-Alb is a better predictor of DN 
progression than glycated hemoglobin in humans with type 
2 diabetes (33). Moreover, AGEs have a cardinal role in the 
progression of vascular dysfunction due to induction of ox-
idative stress and inflammation (34). Proinflammatory cy-
tokines, as TNF-α and IL-6, contribute to renal lesions 
through cellular injury, alteration of the glomerular protein 
permeability barrier, and development of intracranial in-
flammatory damage which lead to diabetic nephropathy 
(35). TPP improved kidney dysfunction in diabetic rats by 
reducing glycation, protein, lipid oxidation, and inflamma-
tory markers (Table 2). In accordance with the results of the 
present study, there is some evidence that indicate the in-
crease in glycated albumin, MGO, and AGEs and the de-
crease in the activity of Glo-1 are associated with nephrop-
athy (4, 10). In this study, for the first time, the healing ef-
fect of thiamine pyrophosphate on renal impairment in type 
2 diabetic rats was reported. 
 
Conclusion 
Thiamine pyrophosphate improves vascular diabetes 
complications by the loweing effect on glycation, oxidative 
stress, and inflammation markers and by an advantageous 
effect on insulin action, the activity of glyoxalase system, 
and lipid profile in the diabetic rats. 
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